Biotron’s Mixed Trial Results and Future Prospects
Biotron Limited (AU:BIT) has released an update.
Biotron Limited reported mixed results from its Phase 2 COVID-19 trial for the antiviral drug BIT225, which met safety and tolerability endpoints but not efficacy targets. Despite this, Biotron continues to advance its research on antiviral compounds, including promising developments in HIV-1 and Dengue virus programs. The company remains committed to exploring commercial opportunities for its unique viroporin antagonist platform, which shows broad-spectrum antiviral activity.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.